Rights and permissions
About this article
Cite this article
Certolizumab pegol dominates in the UK and Finland. Pharmacoecon. Outcomes News 617, 9 (2010). https://doi.org/10.2165/00151234-201006170-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006170-00011